典必殊联合阿昔洛韦治疗单疱病毒性角膜炎的疗效观察

Clinical effect of tobramycin-dexamethasone combined with aciclovir in the treatment of herpes simplex keratitis

目的:探讨典必殊滴眼液联合阿昔洛韦(无环鸟苷,ACV)滴眼液治疗单疱病毒性角膜炎(herpes simplex keratitis,HSK)的疗效。方法:将43例46眼HSK患者随机分两组,典必殊治疗组23例25眼,贝复舒对照组20例21眼,将其临床资料进行回顾性分析,观察临床治疗效果。结果:浅层型全部治愈,深层型典必殊治疗组有效率87.5%,贝复舒对照组有效率60.0%,治愈时间典必殊治疗组平均12d,贝复舒治疗组平均17d;复发率典必殊治疗组34.8%,贝复舒对照组55.0%。两组相比差异有统计学意义(P<0.05)。结论:典必殊联合阿昔洛韦治疗HSK,具有明显的协同作用,能提高治愈率,缩短病程,降低复发,尤其对深层型单疱病毒性角膜炎疗效显著。

AIM：To discuss the effects of tobramycin-dexamethasone（TobraDex） eye drops combined with aciclovir eye drops （ACV） to treat herpes simplex keratitis （HSK） .METHODS： Forty-three cases 46 eyes with HSK were divided into two groups randomly, one group of TobraDex eye drops was with 23 cases 25 eyes,another group of recombinant bovine fibroblast growth factor eye drops was with 20 case 21 eyes, clinical effect was analyzed.RESULTS： The shallow layer was cured completely, the effectiveness of in-depth TobraDex was 87.5%, and that of the group of recombinant bovine fibroblast growth factor was 60.0%, the average cure time of the TobraDex group was 12 days,and recombinant bovine fibroblast growth factor group was 17 days. CONCLUSION： The TobraDex eye drops combined with ACV eye drops to treat HSK can enhance the curative effect, shorten the course and the recrudescence,especially in in-depth HSK.